Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Oct 2 · inside the Ichimoku cloud · RSI 51 · MACD above its signal
None of the 29 investors followed here reported a position in APUS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a APUS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for APUS.
No analyst coverage for this instrument.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.